Buy & Sell GeneDx Holdings Corp (WGS) – GeneDx Holdings Corp Price Today
Aura AI Summary
Key Stats
- $1.21BMarket Cap
- TechnologySector
- -63.49%3M Drawdown
- $1.21BEnterprise Value
- -Dividend Yield
- 2% Buy | 98% SellTrading Activity
- 3 daysTypical Hold Time
GeneDx Holdings Corp (WGS) is currently valued at a market capitalization of $1.21B, with an enterprise value of $1.21B. Over the past 52 weeks, GeneDx Holdings Corp has traded between a low of $34.51 and a high of $167.51, highlighting its annual price range. Over the past three months, GeneDx Holdings Corp has recorded a drawdown of -63.49%, reflecting recent price volatility. On average, investors hold GeneDx Holdings Corp for approximately 3 days, indicating typical investor behavior on the platform.
About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Most Recent News
Bernie Sanders warns Iran war costs could exceed $1 trillion, impacting every US household.
Senator Bernie Sanders criticized the Trump Administration's estimate that the Iran war would cost $25 billion, calling it misleading. He warned the actual cost could surpass $1 trillion, placing a heavy financial burden on American households. Sande...
SEC delays launch of prediction markets ETFs, citing need for further review amid regulatory caution.
The U.S. Securities and Exchange Commission (SEC) has delayed the approval of 24 prediction markets ETFs from firms like Roundhill Investments, Bitwise, and GraniteShares, which were set to launch under the SEC's 75-day automatic approval rule. These...
Health insurers report lower costs but face enrollment drops due to policy changes and lost subsidies.
Major health insurers like UnitedHealthcare, Aetna, Centene, and Elevance Health are seeing improved cost management with lower medical loss ratios in early 2026. However, enrollment in government-subsidized plans is falling sharply as enhanced Obama...